Accessibility Menu
Astellas Pharma logo

Astellas Pharma(OTC) ALPMF

Market Cap$26.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-44%
5 Year+9%
1 Year+40%
1 Month+16%
$14.90
-7.17%
-1.15Today
Astellas Pharma last closing stock price
MetricPriceDate
Last closeUSD 14.902026-08-10
Astellas Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.2%USD 13.772026-08-03
1 month+15.95%USD 12.852026-07-10
3 month-5.4%USD 15.752026-05-12
Year to date+14.88%USD 12.972025-12-30
1 year+39.62%USD 10.672025-08-08
3 year+9.88%USD 13.562023-08-07
5 year+9.43%USD 13.622021-08-10
Since inception-44.28%USD 26.742003-07-15

Astellas Pharma Financials at a Glance

Market Cap

$26.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥2.28T

Net Income (TTM)

¥365.30B

EPS (TTM)

$1.31

P/E Ratio

11.33

Dividend

$0.51

Beta (Volatility)

0.03 (Low)

Price

$14.90

Volume

937

Open

$15.95

Previous Close

$14.90

Daily Range

$14.90 - $15.95

52-Week Range

$9.85 - $17.85

Estimated Earnings Date

Nov 4, 2026

ALPMF News

GettyImages-1146913659

A $20 Billion Sweet Spot in Biotech

David HaenDec 28, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Astellas Pharma

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, focusing on the development, manufacturing, distribution, and commercialization of medicinal products. The company is known for its diverse portfolio, which includes therapies for various medical conditions, particularly in oncology and urology.

Products and Services
  • XTANDI for prostate cancer treatment
  • XOSPATA for acute myeloid leukemia
  • PADCEV for urothelial cancer
Growth Outlook
  • Recent collaborations with leading companies enhance research capabilities
  • Focus on innovative therapies positions Astellas for market expansion
  • Strong pipeline of products expected to drive future revenue growth
Financial Highlights
  • TTM revenue of 2.2 trillion JPY, reflecting robust market demand
  • Net income of 438.9 billion JPY in the latest quarter
  • Operating income margin of 14.5% indicates efficient cost management
Astellas Pharma Inc. has established itself as a significant player in the pharmaceutical industry, with a strong emphasis on research and development. The company's strategic alliances and collaborations with other organizations are designed to enhance its innovative capabilities and expand its product offerings. Recent financial performance demonstrates a solid revenue base and effective cost management, which are critical for sustaining growth in a competitive market. The focus on developing therapies for unmet medical needs positions Astellas favorably for future opportunities.
AI Generated • Jul 25, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

14,099

CEO

Naoki Okamura

Website

www.astellas.com

Headquarters

Tokyo, TY 103-8411, JP

ALPMF Financials

Key Financial Metrics (TTM)

Gross Margin

74.71%

Operating Margin

21.81%

Net Income Margin

16.04%

Return on Equity

20.41%

Return on Capital

17.51%

Return on Assets

9.88%

Earnings Yield

8.83%

Dividend Yield

3.41%

Payout Ratio

38.30%

Stock Overview

Market Cap

$26.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.79B

Volume

937

Avg. Volume

5.31K

Financials (TTM)

Gross Profit

¥1.70T

Operating Income

¥496.73B

EBITDA

¥705.06B

Operating Cash Flow

¥602.03B

Capital Expenditure

-¥57.75B

Free Cash Flow

¥544.28B

Cash & ST Invst.

¥242.93B

Total Debt

¥585.60B

Astellas Pharma Performance Analysis

Astellas Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 11,210,593,310-2.8%
20242024-03-31JPY 11,104,729,504-0.9%
20252025-03-31JPY 12,543,905,53613.0%
20262026-03-31JPY 14,196,133,79713.2%
Astellas Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-305.1%
Q32025-12-317.5%
Q42026-03-31-5.3%
Q12026-06-3017.5%
Astellas Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.40-33.1%
20242024-03-31JPY 0.07-83.6%
20252025-03-31JPY 0.19182.3%
20262026-03-31JPY 1.08481.3%
Astellas Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-3017.3%
Q32025-12-3125.1%
Q42026-03-31-57.1%
Q12026-06-30230.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥636.28B

+25.8%

Gross Profit

¥479.05B

+16.6%

Gross Margin

75.29%

N/A

Market Cap

$26.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.89M

N/A

Employees

14,099

N/A

Net Income

¥140.65B

+105.6%

EBITDA

¥233.93B

+54.1%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥242.93B

+12.8%

Total Debt

¥585.60B

-34.2%

Accounts Receivable

¥838.69B

+25.4%

Inventory

¥335.44B

+9.7%

Long Term Debt

¥317.69B

-43.1%

Short Term Debt

¥267.92B

-19.2%

Return on Assets

9.88%

N/A

Return on Invested Capital

20.18%

N/A

Free Cash Flow

¥74.47B

+77.2%

Operating Cash Flow

¥86.99B

+58.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ORINYOrion Oyj
$43.02+0.00%
WXXWYWuXi Biologics (Cayman) Inc.
$11.79+1.11%
WXIBFWuXi Biologics (Cayman) Inc.
$4.65+0.00%
GNMSFGenmab A/S
$311.51+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$97.52-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.80-0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.73+0.01%
SPCXSpace Exploration Technologies
$138.74+0.04%

Questions About ALPMF

What is the current price of Astellas Pharma?

Astellas Pharma is trading at $14.90 per share.

What is the 52-week range for Astellas Pharma?

Over the past 52 weeks, Astellas Pharma has traded between $9.85 and $17.85.

How much debt does Astellas Pharma have?

As of the most recent reporting period, Astellas Pharma reported total debt of ¥3.63B.

How much cash does Astellas Pharma have on hand?

Astellas Pharma reported ¥1.51B in cash and cash equivalents in its most recent financial results.

What is Astellas Pharma’s dividend yield?

Astellas Pharma currently has a dividend yield of 3.41%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services